AbbVie (ABBV) Operating Expenses (2012 - 2026)
AbbVie (ABBV) posted quarterly Operating Expenses of $11.0 billion for Q1 2026, up 14.59% year-over-year from $9.6 billion in Q1 2025, and down 8.8% quarter-over-quarter from $12.1 billion in Q4 2025.
AbbVie (ABBV) Operating Expenses (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Operating Expenses for 15 consecutive years, with $11.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 14.59% year-over-year to $11.0 billion; the TTM figure through Mar 2026 stood at $47.5 billion (changed 0.41% YoY), while the FY2025 annual figure was $46.1 billion, down 2.36% from the prior year.
- Operating Expenses eased to $11.0 billion in Q1 2026 per ABBV's latest filing, from $12.1 billion in the prior quarter.
- Across five years, Operating Expenses topped out at $16.6 billion in Q4 2024 and bottomed at $8.8 billion in Q1 2022.
- Historically, Operating Expenses has averaged $10.9 billion across 5 years, with a median of $10.5 billion in 2025.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 49.4% — and 2025, when it fell 27.23%.
- AbbVie's Operating Expenses stood at $9.6 billion in 2022, then grew by 15.46% to $11.1 billion in 2023, then soared by 49.4% to $16.6 billion in 2024, then decreased by 27.23% to $12.1 billion in 2025, then slipped by 8.8% to $11.0 billion in 2026.
- Business Quant data shows ABBV's Operating Expenses at $11.0 billion in Q1 2026, $12.1 billion in Q4 2025, and $13.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.49 Bn | 632.73 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 470.91 Bn | 464.34 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 379.63 Bn | 372.49 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 258.40 Bn | 253.50 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 237.10 Bn | 223.11 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 161.60 Bn | 149.90 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.86 Bn | 101.70 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 55.22 Bn | 47.84 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.56 Bn |
| Mar 31, 2026 | 11.01 Bn |
| Dec 31, 2025 | 12.07 Bn |
| Sep 30, 2025 | 13.87 Bn |
| Jun 30, 2025 | 10.53 Bn |
| Mar 31, 2025 | 9.61 Bn |
| Dec 31, 2024 | 16.59 Bn |
| Sep 30, 2024 | 10.63 Bn |
| Jun 30, 2024 | 10.46 Bn |
| Mar 31, 2024 | 9.51 Bn |
| Dec 31, 2023 | 11.11 Bn |
| Sep 30, 2023 | 11.65 Bn |
| Jun 30, 2023 | 9.35 Bn |
| Mar 31, 2023 | 9.46 Bn |
| Dec 31, 2022 | 9.62 Bn |
| Sep 30, 2022 | 10.21 Bn |
| Jun 30, 2022 | 11.29 Bn |
| Mar 31, 2022 | 8.82 Bn |
| Dec 31, 2021 | 9.81 Bn |
| Sep 30, 2021 | 10.04 Bn |